Skip to main content

Becton Dickinson Value Stock - Dividend - Research Selection

Becton dickinson

ISIN: US0758871091 , WKN: 857675

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women\'s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views

2026-08-09
Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching closely. This shift reflects how recent research is weighing the solid fiscal Q3 beat, product updates, and mixed views on 2027 utilization and margin risk. As you read on, you will see how these moving pieces shape the evolving narrative around Becton Dickinson and what that could mean for your own assessment of the stock. Stay...

Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships

2026-08-09
Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results, with sales rising to US$4,983 million while net income fell to US$377 million, and modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. Alongside these earnings, BD highlighted strong momentum in biologic drug delivery and GLP-1–related partnerships, including a new semaglutide pen collaboration with EMS in Brazil, underscoring the growing role of its Vystra Injection Pen...

Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ...

2026-08-08
BDX beats expectations with 4.4% FX-neutral revenue growth, raises full-year EPS guidance, and outlines strategic plans to navigate fiscal 2027 headwinds.

Becton, Dickinson and Company Q3 Earnings Call Highlights

2026-08-08
Becton, Dickinson and Company (NYSE:BDX) reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company’s expectations. Chairman, Chief Executive Officer and President Tom Po

Citigroup Maintains Buy on Becton Dickinson, Raises Price Target to $204

2026-08-07
Citigroup analyst Joanna Wiensch maintains Becton Dickinson (NYSE:BDX) with a Buy and raises the price target from $198 to $204.

RBC Capital Maintains Sector Perform on Becton Dickinson, Raises Price Target to $180

2026-08-07
RBC Capital analyst Kendall Au maintains Becton Dickinson (NYSE:BDX) with a Sector Perform and raises the price target from $175 to $180.

Piper Sandler Maintains Neutral on Becton Dickinson, Raises Price Target to $175

2026-08-07
Piper Sandler analyst Jason Bednar maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $161 to $175.

Wells Fargo Maintains Equal-Weight on Becton Dickinson, Raises Price Target to $170

2026-08-07
Wells Fargo analyst Lawrence Biegelsen maintains Becton Dickinson (NYSE:BDX) with a Equal-Weight and raises the price target from $161 to $170.

Becton, Dickinson and Company Q3 2026 Earnings Call Summary

2026-08-06
Moby summary of Becton, Dickinson and Company's Q3 2026 earnings call

BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down

2026-08-06
BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.